China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (ANG2) for intravitreal injection in the treatment of neovascular age-related macular degeneration (nAMD).
Category 1 Biologic Product Features and Benefits
This Category 1 biologic product is engineered with distinctive nano antibodies and is tailored for the treatment of retinal neovascular diseases. The tetravalent bispecific antibody boasts several differentiating advantages, including high affinity, potent inhibitory activity, a high concentration formulation, excellent stability, and a low administration frequency. These characteristics position it as a safer and more effective treatment option for patients suffering from retinal neovascular diseases, potentially offering a more convenient therapy regimen.
Implications for Retinal Disease Treatment
The development and potential approval of CMS’s tetravalent BsAb could significantly impact the treatment landscape for nAMD, a leading cause of severe vision loss in older adults. By targeting both VEGFA and ANG2, the antibody may provide a more comprehensive treatment approach, addressing key pathways in retinal neovascularization. The high concentration and stability of the formulation, along with the potential for less frequent dosing, could enhance patient compliance and quality of life.-Fineline Info & Tech
